Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Inflammatix, Inc. logo — We’re reimagining diagnostics by reading the immune system

Inflammatix, Inc.

We’re reimagining diagnostics by reading the immune system

Founded 2016 United States Sunnyvale, United States 96 employees Grant Total: $137.80M Big Data, Biotechnology +2

General Information

Company Name Inflammatix, Inc.
Founded Year 2016
Location United States Sunnyvale, United States +1
Employees 96
Industries Big Data, Biotechnology, Health Care +1
Funding Stage Grant
Social

Get notified when Inflammatix, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Inflammatix, Inc.

Inflammatix, Inc. is a U.S.-based startup that is revolutionizing diagnostics through its innovative approach of tapping into the immune system. Founded in 2016, the company's mission is reflected in its slogan "We're reimagining diagnostics by reading the immune system." Inflammatix is focused on developing a pioneering point-of-care instrument platform that works in conjunction with a test to facilitate the diagnosis of acute infection and sepsis by leveraging advanced immune response diagnostics. This breakthrough technology is designed to rapidly provide clinicians with crucial information about the likelihood of bacterial or viral infection, as well as the necessity for ICU level care in emergency departments. The faster results delivered by the platform have the potential to lead to more prompt and suitable therapy, as well as decisions regarding the level of care required. In November 2021, the company received a significant grant investment of $1.70M from the National Institutes of Health. It's important to note that the products developed by Inflammatix are still in the developmental phase and have not yet received marketing approval or regulatory clearance in any jurisdiction. With its focus on big data, biotechnology, and healthcare, Inflammatix is poised to continue making strides in the field of diagnostics and providing critical solutions for acute infections and sepsis.

Taxonomy: diagnostics, point-of-care testing, immune system, acute infection, sepsis, immune response diagnostics, bacterial infection, viral infection, ICU care, emergency department, therapy decisions, clinical innovation, regulatory approval

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 11 Nov 2021
Series D •••••• 6
Investor Investor Investor Investor
•••• •••• 		16 Mar 2021
Grant •••••• 1
Investor
29 Sep 2020
Series C •••••• 4
Investor Investor Investor
•••• •••• 		10 Jan 2020
Series B •••••• 2
Investor
•••• •••• 		18 Oct 2018

View All 7 Funding Rounds

Inflammatix, Inc. Alternatives & Competitors

Inflammatix, Inc. vs
Loop Dx
Loop Dx Spain

Cell-mediated immune response diagnostics to predict sepsis early, enabling timely treatment and sav...

Seed
12 employees
Health Care
Compare Inflammatix, Inc. vs Loop Dx
Inflammatix, Inc. vs
Immune Tolerance Network
Immune Tolerance Network

The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the N...

36 employees
Inflammatix, Inc. vs
Cytovale
Cytovale United States

At Cytovale, we’re focused on more rapid and insightful ways to diagnose fast-moving and immune-medi...

Series C
121 employees
AI, Health Care
Compare Inflammatix, Inc. vs Cytovale
Also compare with: Inflammatix, Inc. vs Lyfstone Lyfstone

FAQ About Inflammatix, Inc.

We’re reimagining diagnostics by reading the immune system
Inflammatix, Inc. was founded in 2016.
Inflammatix, Inc. is headquartered in Sunnyvale, United States.
Inflammatix, Inc. operates in the following industries: Big Data, Biotechnology, Health Care, Clean Energy.
Inflammatix, Inc. has approximately 96 employees.
Inflammatix, Inc. has completed 7 funding rounds, raising a total of $137.80M. The latest funding stage is Grant.
Top alternatives and competitors to Inflammatix, Inc. include Loop Dx, Immune Tolerance Network, Cytovale, Lyfstone, HalioDx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inflammatix, Inc. and Loop Dx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Inflammatix, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy